Literature DB >> 8610217

Primary Sjögren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS.

P Zufferey1, O C Meyer, M Grossin, M F Kahn.   

Abstract

The aim of this study was to assess the prevalence of malignant lymphomas in patients with long-standing primary Sjögren's syndrome (pSS). We retrospectively studied a cohort of 55 patients with pSS over a mean follow-up period of 12 years. Five patients (9%) developed malignant lymphoma. The interval between the diagnoses of SS and lymphoma ranged from four to 12 years (mean = 6.5 years). The lymphoma arose in the lymph nodes in two cases, the parotid gland in one case, the lacrimal gland in one case, and the lung in one case. All five cases were B-cell low-grade lymphomas. Among our SS patients, those with extraglandular manifestations and/or a mixed cryoglobulin were at increased risk for lymphoma development. Secondary lymphoma carried a poor prognosis in our study. Three of the six SS patients who died during the follow-up period had lymphoma.

Entities:  

Mesh:

Year:  1995        PMID: 8610217     DOI: 10.3109/03009749509095178

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  17 in total

Review 1.  Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.

Authors:  Ibtisam Al-Hashimi
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects.

Authors:  M Pertovaara; E Pukkala; P Laippala; A Miettinen; A Pasternack
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 3.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Active immunological profile is associated with systemic Sjögren's syndrome.

Authors:  Clothilde Martel; Guillaume Gondran; David Launay; Fabrice Lalloué; Sylvain Palat; Marc Lambert; Kim Ly; Veronique Loustaud-Ratti; Holly Bezanahary; Eric Hachulla; Marie Odile Jauberteau; Elisabeth Vidal; Pierre Yves Hatron; Anne Laure Fauchais
Journal:  J Clin Immunol       Date:  2011-07-09       Impact factor: 8.317

5.  Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both).

Authors:  M Pertovaara; M Korpela; H Uusitalo; J Pukander; A Miettinen; H Helin; A Pasternack
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

6.  Sjögren's syndrome: History, clinical and pathological features.

Authors:  A L Parke; W W Buchanan
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

Review 7.  Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.

Authors:  Maria B Nishishinya; Claudia A Pereda; Santiago Muñoz-Fernández; José M Pego-Reigosa; Iñigo Rúa-Figueroa; José-Luis Andreu; Mónica Fernández-Castro; José Rosas; Estibaliz Loza Santamaría
Journal:  Rheumatol Int       Date:  2014-06-05       Impact factor: 2.631

8.  Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.

Authors:  Aristea Papageorgiou; Dimitrios C Ziogas; Clio P Mavragani; Elias Zintzaras; Athanasios G Tzioufas; Haralampos M Moutsopoulos; Michael Voulgarelis
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

9.  MALT Lymphoma of Minor Salivary Glands in a Sjögren's Syndrome Patient: a Case Report and Review of Literature.

Authors:  Savvas Titsinides; Nikolaos Nikitakis; Evangelia Piperi; Alexandra Sklavounou
Journal:  J Oral Maxillofac Res       Date:  2017-03-31

10.  Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study.

Authors:  Sung Hae Chang; Jin Kyun Park; Yun Jong Lee; Ji Ae Yang; Eun Young Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Arthritis Res Ther       Date:  2014-08-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.